PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.

Laura S van DamEbru DirikgilEdwin W BredewoldArgho RayJaap Adriaan BakkerCees van KootenTon J RabelinkYoe K Onno Teng

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021)

Upon RI treatment with RTX in AAV patients, ANCA and B-cell status were predictive of the majority of relapses and specifically their absence strongly predicted a relapse-free status. Therefore the implementation of ANCA and B-cell monitoring could guide therapeutic decision-making to prevent relapses in AAV patients treated with RTX.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
decision making
peritoneal dialysis
healthcare
primary care
prognostic factors